DiaMedica Appoints John Savage as Chief Financial Officer
April 07 2014 - 8:07AM
Marketwired
DiaMedica Appoints John Savage as Chief Financial Officer
MINNEAPOLIS, MINNESOTA--(Marketwired - Apr 7, 2014) - DiaMedica
(TSX-VENTURE:DMA) today announced the appointment of Mr. John
Savage as the Company's Chief Financial Officer. Mr. Savage has
more than 17 years of experience working with publicly traded
companies.
"We are delighted to welcome John to DiaMedica," said Rick
Pauls, DiaMedica's President and CEO. "John brings a combination of
strong financial and corporate experience with publicly traded
companies to help advance DiaMedica's business strategy."
Prior to joining DiaMedica, Mr. Savage was Director of Corporate
Accounting at UnitedHealth Group, a diversified health care
company, where he also was involved in the Diabetes Prevention and
Control Alliance (DPCA). Previously, Mr. Savage was with Best Buy
and Golf Galaxy (acquired by Dick's Sporting Goods), where he held
increasingly progressive responsibilities. Mr. Savage began his
career with Deloitte & Touche LLP. He graduated Summa Cum
Laude from the University of St. Thomas with a Bachelor of
Arts degree in Business Administration.
The Company issued Mr. Savage 200,000 stock options in
accordance with the Stock Option Plan at an exercise price of CAD
$0.83 and a term of 10 years. The options are subject to acceptance
by the TSX Venture Exchange.
About DiaMedica
DiaMedica Inc. is a publicly traded (TSX-VENTURE:DMA) clinical
stage biopharmaceutical company focused on the discovery and
development of novel therapies to treat diabetes and the
complications associated with diabetes. DiaMedica's lead clinical
stage compound, DM199, is a recombinant human protein known as
rhKLK1 that represents a novel approach to treating diabetes and
associated complications. DiaMedica is also developing a novel
monoclonal antibody, DM204 for the treatment of Type 2 diabetes,
which is in preclinical development.
The Company is listed on the TSX Venture Exchange in Canada
under the trading symbol 'DMA'.
FORWARD-LOOKING STATEMENTS
The statements made in this press release that are not
historical facts contain forward-looking information that involves
risk and uncertainties. All statements, other than statements of
historical facts, which address DiaMedica's expectations, should be
considered forward-looking statements. Such statements are based on
management's exercise of business judgment as well as assumptions
made by and information currently available to management. When
used in this document, the words "may", "will", "anticipate",
"believe", "estimate", "expect", "intend" and words of similar
import, are intended to identify any forward-looking statements.
You should not place undue reliance on these forward-looking
statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as
contained in the Corporation's filings with Canadian securities
regulatory authorities. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Corporation
undertakes no obligation, and does not intend, to update, revise or
otherwise publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date
hereof, or to reflect the occurrence of any unanticipated events.
Although management believes that expectations are based on
reasonable assumptions, no assurance can be given that these
expectations will materialize.
DiaMedica Inc.Rick PaulsPresident &
CEO763-710-4455info@diamedica.com
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Oct 2024 to Nov 2024
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Nov 2023 to Nov 2024
